Myriad Weighs Separation Of Diagnostics, Drug Businesses
This article was originally published in The Gray Sheet
Executive Summary
As Myriad Genetics moves into a new phase - achieving profitability in fiscal 2008 for the first time - the company is seeking to develop a new corporate strategy to drive growth, which could include a sale or spin off of its pharma business, the firm said during its fiscal 2008 sales and earnings call Aug. 19